Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.41 |
| ▸ | CES1 | P23141 | 3/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 3/20 | 0.32 |
| ▸ | CA2 | P00918 | 3/20 | 0.32 |
| ▸ | CA4 | P22748 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.32 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphine SCHEMBL28191590 | 0.97 | CES2 (0.39) | CES2CES1TTRCA1CA2 | |
| SCHEMBL11992628 | 0.80 | RAPGEF4 (0.34) | TTRRAPGEF4 | |
| SCHEMBL18101290 | 0.79 | TTR (0.33) | TTR | |
| SCHEMBL15076679 | 0.78 | — | — | |
| SCHEMBL3062133 | 0.76 | SLC6A4 (0.31) | CES2CES1 | |
| SCHEMBL22449911 | 0.76 | GABRA1 (0.33) | — | |
| SCHEMBL3066902 | 0.74 | ERN1 (0.47) | CES2CES1 | |
| SCHEMBL855169 | 0.73 | KDM1A (0.39) | TTR | |
| SCHEMBL752725 | 0.73 | HDAC1 (0.39) | TTR | |
| SCHEMBL1095914 | 0.73 | CA1 (0.41) | TTRCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102153559-B | Method for synthesizing sitagliptin phosphate and derivatives thereof | NANJING UNIVERSITY OF TECHNOLOGY | 2013-04-24 | — | — | CN | claimed |
| EP-1362860-B1 | Method for producing tetrakis (fluoraryl)borate magnesium compound | NIPPON CATALYTIC CHEM IND (JP) | 2010-09-15 | — | — | EP | claimed |
| US-7205441-B2 | Method for producing tetrakis (fluoroaryl) borate-magnesium compound | NIPPON SHOKUBAI CO., LTD. (JP) | 2007-04-17 | — | — | US | claimed |
| US-20030216598-A1 | Method for producing tetrakis ( fluoroaryl) borate-magnesium compound | NIPPON SHOKUBAI CO., LTD. (JP) | 2003-11-20 | — | — | US | claimed |
| EP-1362860-A1 | Method for producing tetrakis (fluoroaryl) borate magnesium compound | Nippon Shokubai Co., Ltd. (JP) | 2003-11-19 | — | — | EP | claimed |
| EP-4665495-A1 | DEVELOPMENT OF LIGANDS FOR METALS AND METAL-CATALYZED REACTIONS | Indian Institute of Technology Bombay (IN) | 2025-12-24 | — | — | EP | disclosed |
| US-12268687-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2025-04-08 | — | — | US | disclosed |
| US-20250034124-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-30 | — | — | US | disclosed |
| US-20250034125-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-30 | — | — | US | disclosed |
| US-20240425512-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF | 280 BIO, INC. (US) | 2024-12-26 | — | — | US | disclosed |
| WO-2024254404-A2 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF | 280 BIO, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| CN-119101070-A | Nitrogen-containing heterocyclic compound, pharmaceutical composition and application thereof | 上海璎黎药业有限公司 | 2024-12-10 | — | — | CN | disclosed |
| CN-1356331-A | Process for preparing metallic fluoroaryl ampound | NIPPON CATALYTIC CHEM IND (JP) | 2002-07-03 | — | — | CN | disclosed |
| EP-1211255-A2 | Method for producing fluoroaryl metal compound | Nippon Shokubai Co., Ltd. (JP) | 2002-06-05 | — | — | EP | disclosed |
| US-20020065426-A1 | Method for producing fluoroaryl metal compound | NIPPON SHOKUBAI CO., LTD (JP) | 2002-05-30 | — | — | US | disclosed |
| US-6235222-B1 | REACTING, IN SOLVENT CONTAINING CHAIN ETHER SOLVENT, HYDROCARBON MAGNESIUM HALIDE WITH FLUOROARYL HALIDE | NIPPON SHOKUBAI CO., LTD. (JP) | 2001-05-22 | — | — | US | disclosed |
| EP-0995753-A2 | Method for manufacturing fluoroaryl magnesium halide | Nippon Shokubai Co., Ltd. (JP) | 2000-04-26 | — | — | EP | disclosed |
| EP-0109606-B1 | PROCESS FOR THE FORMYLATION OF ARYL HALIDES | BAYER AG (DE) | 1986-01-22 | — | — | EP | disclosed |
| US-4536344-A | USING A PHOSPINE OR PHOSPHITE | BAYER AKTIENGESELLSCHAFT (DE) | 1985-08-20 | — | — | US | disclosed |
| EP-0109606-A1 | Process for the formylation of aryl halides | BAYER AG (DE) | 1984-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034124-A1 | COMPOUNDS AND USES THEREOF | NLN, BDNF, NQO1 | CES2 228/4885CES1 1769/4885TTR 4376/4885 |
| US-20030216598-A1 | Method for producing tetrakis ( fluoroaryl) borate-magnesium compound | KRAS, MGAM, CA3 | CES2 3957/4885CES1 4605/4885TTR 1232/4885 |
| US-12268687-B2 | Compounds and uses thereof | NLN, BDNF, NQO1 | CES2 228/4885CES1 1769/4885TTR 4376/4885 |
| US-20240425512-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF | KRAS, NRAS, HRAS | CES2 4804/4885CES1 4124/4885TTR 565/4885 |
| US-20020065426-A1 | Method for producing fluoroaryl metal compound | DDT, TERT, HACL2 | CES2 3276/4885CES1 3890/4885TTR 257/4885 |
| US-20250034125-A1 | COMPOUNDS AND USES THEREOF | NLN, BDNF, NQO1 | CES2 228/4885CES1 1769/4885TTR 4376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.